BARDA grants $15m contract to RxBio
The contract is valued at up to $24m for the upcoming two years. The company expects to facilitate the development of Rx100, a radiomitigant countermeasure drug used against
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement. ECLIPSE II is an open-label, dose-escalating study, where CYT107 was administered subcutaneously, one injection